BioNTech to Provide an Update on Manufacturing and Development Plans of mRNA Vaccines in AfricaGlobeNewsWire • 06/09/22
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCOGlobeNewsWire • 06/05/22
Pfizer/BioNTech say third vaccine dose is 80% effective against Omicron in kids 5 and youngerProactive Investors • 05/23/22
Pfizer, BioNTech COVID-19 vaccine for children aged 6 months to 5 years meets EUA criteriaMarket Watch • 05/23/22
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third DoseBusiness Wire • 05/23/22
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of AgeBusiness Wire • 05/17/22
FDA authorizes a booster dose of BioNTech/Pfizer's vaccine for 5 to 11 year oldsMarket Watch • 05/17/22
BioNTech SE (BNTX) CEO Ugur Sahin on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22